ALNY logo

Alnylam Pharmaceuticals (ALNY) Cash from operations

annual CFO:

-$8.31M-$112.47M(-107.98%)
December 31, 2024

Summary

  • As of today (May 29, 2025), ALNY annual cash flow from operations is -$8.31 million, with the most recent change of -$112.47 million (-107.98%) on December 31, 2024.
  • During the last 3 years, ALNY annual CFO has risen by +$633.38 million (+98.70%).
  • ALNY annual CFO is now -104.23% below its all-time high of $196.52 million, reached on December 31, 2007.

Performance

ALNY Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherALNYcash flow metrics

quarterly CFO:

-$118.31M-$23.65M(-24.99%)
March 31, 2025

Summary

  • As of today (May 29, 2025), ALNY quarterly cash flow from operations is -$118.31 million, with the most recent change of -$23.65 million (-24.99%) on March 31, 2025.
  • Over the past year, ALNY quarterly CFO has dropped by -$36.80 million (-45.14%).
  • ALNY quarterly CFO is now -132.92% below its all-time high of $359.41 million, reached on September 30, 2023.

Performance

ALNY quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherALNYcash flow metrics

TTM CFO:

-$45.11M-$36.80M(-442.72%)
March 31, 2025

Summary

  • As of today (May 29, 2025), ALNY TTM cash flow from operations is -$45.11 million, with the most recent change of -$36.80 million (-442.72%) on March 31, 2025.
  • Over the past year, ALNY TTM CFO has dropped by -$234.23 million (-123.85%).
  • ALNY TTM CFO is now -112.12% below its all-time high of $372.26 million, reached on June 30, 2024.

Performance

ALNY TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherALNYcash flow metrics

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

ALNY Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-108.0%-45.1%-123.8%
3 y3 years+98.7%+30.9%+92.2%
5 y5 years+97.0%+51.9%+86.6%

ALNY Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-108.0%+98.7%-132.9%+30.9%-112.1%+92.2%
5 y5-year-108.0%+98.7%-132.9%+51.9%-112.1%+94.1%
alltimeall time-104.2%+98.7%-132.9%+51.9%-112.1%+94.1%

ALNY Cash from operations History

DateAnnualQuarterlyTTM
Mar 2025
-
-$118.31M(+25.0%)
-$45.11M(+442.7%)
Dec 2024
-$8.31M(-108.0%)
-$94.66M(-316.6%)
-$8.31M(-114.7%)
Sep 2024
-
$43.71M(-64.8%)
$56.55M(-84.8%)
Jun 2024
-
$124.16M(-252.3%)
$372.26M(+96.8%)
Mar 2024
-
-$81.52M(+173.6%)
$189.12M(+81.6%)
Dec 2023
$104.16M(-119.2%)
-$29.80M(-108.3%)
$104.16M(+5179.1%)
Sep 2023
-
$359.41M(-709.3%)
$1.97M(-100.4%)
Jun 2023
-
-$58.99M(-64.6%)
-$472.72M(-11.9%)
Mar 2023
-
-$166.47M(+26.1%)
-$536.56M(-0.9%)
Dec 2022
-$541.27M(-15.6%)
-$131.98M(+14.5%)
-$541.27M(-3.2%)
Sep 2022
-
-$115.28M(-6.1%)
-$559.44M(-3.2%)
Jun 2022
-
-$122.82M(-28.3%)
-$578.19M(+0.2%)
Mar 2022
-
-$171.19M(+14.0%)
-$577.23M(-10.0%)
Dec 2021
-$641.69M(+4.3%)
-$150.14M(+12.0%)
-$641.69M(+4.4%)
Sep 2021
-
-$134.04M(+10.0%)
-$614.70M(+4.0%)
Jun 2021
-
-$121.86M(-48.3%)
-$590.99M(-2.2%)
Mar 2021
-
-$235.66M(+91.4%)
-$604.46M(-1.7%)
Dec 2020
-$614.96M(+120.9%)
-$123.14M(+11.6%)
-$614.96M(-10.6%)
Sep 2020
-
-$110.33M(-18.5%)
-$687.80M(-9.5%)
Jun 2020
-
-$135.33M(-45.0%)
-$760.10M(+126.2%)
Mar 2020
-
-$246.16M(+25.6%)
-$336.08M(+20.7%)
Dec 2019
-$278.43M(-50.5%)
-$195.98M(+7.3%)
-$278.43M(+19.5%)
Sep 2019
-
-$182.63M(-163.3%)
-$232.90M(+14.1%)
Jun 2019
-
$288.69M(-253.1%)
-$204.08M(-65.7%)
Mar 2019
-
-$188.51M(+25.3%)
-$595.46M(+5.8%)
Dec 2018
-$562.62M(+47.0%)
-$150.46M(-2.2%)
-$562.62M(+9.2%)
Sep 2018
-
-$153.81M(+49.8%)
-$515.20M(+12.1%)
Jun 2018
-
-$102.69M(-34.0%)
-$459.76M(+4.9%)
Mar 2018
-
-$155.66M(+51.1%)
-$438.12M(+14.5%)
Dec 2017
-$382.79M(+24.4%)
-$103.04M(+4.8%)
-$382.79M(+6.9%)
Sep 2017
-
-$98.36M(+21.4%)
-$358.08M(+6.8%)
Jun 2017
-
-$81.05M(-19.2%)
-$335.25M(+3.3%)
Mar 2017
-
-$100.33M(+28.1%)
-$324.41M(+5.4%)
Dec 2016
-$307.70M(+62.7%)
-$78.34M(+3.7%)
-$307.70M(+8.9%)
Sep 2016
-
-$75.54M(+7.6%)
-$282.43M(+8.1%)
Jun 2016
-
-$70.20M(-16.0%)
-$261.26M(+6.0%)
Mar 2016
-
-$83.62M(+57.6%)
-$246.51M(+30.3%)
Dec 2015
-$189.14M(+14.2%)
-$53.06M(-2.4%)
-$189.14M(+9.5%)
Sep 2015
-
-$54.37M(-2.0%)
-$172.71M(+8.6%)
Jun 2015
-
-$55.46M(+111.2%)
-$159.05M(+5.9%)
Mar 2015
-
-$26.25M(-28.3%)
-$150.22M(-9.3%)
Dec 2014
-$165.64M
-$36.63M(-10.0%)
-$165.64M(+9.4%)
Sep 2014
-
-$40.71M(-12.7%)
-$151.38M(+14.3%)
DateAnnualQuarterlyTTM
Jun 2014
-
-$46.63M(+11.9%)
-$132.38M(+21.1%)
Mar 2014
-
-$41.67M(+86.3%)
-$109.36M(+59.3%)
Dec 2013
-$68.66M(-40.6%)
-$22.37M(+3.0%)
-$68.66M(-40.4%)
Sep 2013
-
-$21.71M(-8.0%)
-$115.20M(+30.5%)
Jun 2013
-
-$23.60M(+2330.7%)
-$88.27M(+2.2%)
Mar 2013
-
-$971.00K(-98.6%)
-$86.36M(-25.3%)
Dec 2012
-$115.61M(+32.8%)
-$68.91M(-1422.2%)
-$115.61M(+60.9%)
Sep 2012
-
$5.21M(-124.0%)
-$71.86M(-32.3%)
Jun 2012
-
-$21.69M(-28.2%)
-$106.09M(-4.4%)
Mar 2012
-
-$30.21M(+20.1%)
-$110.98M(+27.5%)
Dec 2011
-$87.07M(+3.2%)
-$25.16M(-13.3%)
-$87.07M(+5.8%)
Sep 2011
-
-$29.02M(+9.2%)
-$82.30M(+6.5%)
Jun 2011
-
-$26.58M(+321.6%)
-$77.31M(+3.0%)
Mar 2011
-
-$6.30M(-69.1%)
-$75.05M(-11.0%)
Dec 2010
-$84.34M(+16.9%)
-$20.39M(-15.2%)
-$84.34M(+4.4%)
Sep 2010
-
-$24.04M(-1.1%)
-$80.82M(+4.5%)
Jun 2010
-
-$24.31M(+55.8%)
-$77.37M(-13.0%)
Mar 2010
-
-$15.60M(-7.5%)
-$88.98M(+23.3%)
Dec 2009
-$72.14M(-210.2%)
-$16.87M(-18.1%)
-$72.14M(+20.0%)
Sep 2009
-
-$20.59M(-42.7%)
-$60.13M(+8.2%)
Jun 2009
-
-$35.92M(-3017.9%)
-$55.55M(-173.7%)
Mar 2009
-
$1.23M(-125.4%)
$75.38M(+15.1%)
Dec 2008
$65.49M(-66.7%)
-$4.85M(-69.7%)
$65.49M(+5.8%)
Sep 2008
-
-$16.01M(-116.9%)
$61.90M(-79.5%)
Jun 2008
-
$95.01M(-1197.3%)
$302.22M(+52.0%)
Mar 2008
-
-$8.66M(+2.6%)
$198.82M(+1.2%)
Dec 2007
$196.52M(-897.9%)
-$8.44M(-103.8%)
$196.52M(-1.9%)
Sep 2007
-
$224.31M(-2773.2%)
$200.34M(-844.9%)
Jun 2007
-
-$8.39M(-23.4%)
-$26.90M(+0.0%)
Mar 2007
-
-$10.96M(+137.6%)
-$26.89M(+9.2%)
Dec 2006
-$24.63M(+49.4%)
-$4.61M(+57.3%)
-$24.63M(+50.2%)
Sep 2006
-
-$2.93M(-65.0%)
-$16.40M(-16.7%)
Jun 2006
-
-$8.38M(-3.7%)
-$19.68M(+12.1%)
Mar 2006
-
-$8.70M(-340.7%)
-$17.55M(+6.5%)
Dec 2005
-$16.48M(-15.8%)
$3.62M(-158.2%)
-$16.48M(-21.9%)
Sep 2005
-
-$6.21M(-0.6%)
-$21.12M(+14.0%)
Jun 2005
-
-$6.25M(-18.2%)
-$18.52M(-1.1%)
Mar 2005
-
-$7.64M(+651.9%)
-$18.71M(-4.4%)
Dec 2004
-$19.57M(+52.6%)
-$1.02M(-71.9%)
-$19.57M(+5.5%)
Sep 2004
-
-$3.61M(-44.0%)
-$18.55M(+24.2%)
Jun 2004
-
-$6.45M(-24.1%)
-$14.94M(+75.9%)
Mar 2004
-
-$8.49M
-$8.49M
Dec 2003
-$12.83M(+903.8%)
-
-
Dec 2002
-$1.28M
-
-

FAQ

  • What is Alnylam Pharmaceuticals annual cash flow from operations?
  • What is the all time high annual CFO for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals annual CFO year-on-year change?
  • What is Alnylam Pharmaceuticals quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals quarterly CFO year-on-year change?
  • What is Alnylam Pharmaceuticals TTM cash flow from operations?
  • What is the all time high TTM CFO for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals TTM CFO year-on-year change?

What is Alnylam Pharmaceuticals annual cash flow from operations?

The current annual CFO of ALNY is -$8.31M

What is the all time high annual CFO for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high annual cash flow from operations is $196.52M

What is Alnylam Pharmaceuticals annual CFO year-on-year change?

Over the past year, ALNY annual cash flow from operations has changed by -$112.47M (-107.98%)

What is Alnylam Pharmaceuticals quarterly cash flow from operations?

The current quarterly CFO of ALNY is -$118.31M

What is the all time high quarterly CFO for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high quarterly cash flow from operations is $359.41M

What is Alnylam Pharmaceuticals quarterly CFO year-on-year change?

Over the past year, ALNY quarterly cash flow from operations has changed by -$36.80M (-45.14%)

What is Alnylam Pharmaceuticals TTM cash flow from operations?

The current TTM CFO of ALNY is -$45.11M

What is the all time high TTM CFO for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high TTM cash flow from operations is $372.26M

What is Alnylam Pharmaceuticals TTM CFO year-on-year change?

Over the past year, ALNY TTM cash flow from operations has changed by -$234.23M (-123.85%)
On this page